PRVA

As of 2026-10-26, PRVA scores 45out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. PRVA trades at $22.16, 4% above the band ceiling.

PRVA scores 45 out of 100 on QNTM's five-factor model — a low-conviction reading — at 45 the factor profile is among the weaker names in the universe. Its strongest factor is value at 68 (strong), where it screens cheap on the model's valuation inputs, followed by volume at 48. The weakest is momentum at 33, where price trend is the soft spot. Among Healthcare stocks it sits in the lower 30% of Healthcare names by composite.

On valuation, PRVA is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 45. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on PRVA, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where PRVA sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for PRVA runs $15.86–$21.37. Current price $22.16 sits 4% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.